Skip to main content
DBVT
NASDAQ Life Sciences

DBV Technologies Secures €166.7M from Warrant Exercise, Funds Operations and Viaskin Peanut Launch

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$21.1
Mkt Cap
$878.695M
52W Low
$3.8
52W High
$26.185
52W Position info
455% above low
Off High info
19% below high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

DBVT has more than doubled off its 52-week low of $3.8.

Summary

DBV Technologies announced the full exercise of warrants from its March 2025 financing, generating €166.7 million in gross proceeds to fund operations, BLA submission, and the potential U.S. launch of its Viaskin Peanut patch.


Key Events · Financing and Capital Events · DBVT

  • Warrant Exercise Completed

    DBV Technologies announced the full exercise of ABSA and BS warrants issued during its March 2025 financing.

  • Significant Capital Raise

    The full exercise of warrants generated €166.7 million in gross proceeds for the company.

  • Extended Cash Runway

    The proceeds, combined with existing cash, are projected to fund operations for at least the next 12 months.

  • Going Concern Risk Mitigated

    The company explicitly stated that there is no substantial doubt about its ability to continue as a going concern.


Analysis · DBVT · Life Sciences

This substantial capital infusion, representing a significant portion of the company's market capitalization, critically strengthens DBV Technologies' financial position. The proceeds, combined with existing cash, are expected to fund operations for at least the next 12 months, explicitly removing substantial doubt about the company's ability to continue as a going concern. This funding is essential for advancing the Biologics License Application (BLA) and preparing for the potential commercial launch of the Viaskin Peanut patch, especially following recent positive VITESSE trial results. While the exercise of warrants is dilutive, the successful securing of this capital is a strong positive signal for the company's operational stability and its ability to bring its key product to market.

At the time of this filing, DBVT was trading at $21.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $878.7M. The 52-week trading range was $3.80 to $26.19. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DBVT - Latest Insights

DBVT
Jul 27, 2026, 7:46 AM EDT
Filing Type: S-3ASR
Importance Score:
7
Price at Filing: $13.77
Real-time Price: $13.85 info
Change: +$0.080 (+0.58%) info
Market Cap: $800.711M info
DBVT
Jul 16, 2026, 5:02 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.86
Real-time Price: $13.85 info
Change: -$1.01 (-7%) info
Market Cap: $800.711M info
DBVT
Jul 16, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $14.86
Real-time Price: $13.85 info
Change: -$1.01 (-7%) info
Market Cap: $800.711M info
DBVT
Jun 29, 2026, 4:28 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $16.00
Real-time Price: $13.85 info
Change: -$2.15 (-13%) info
Market Cap: $800.711M info
DBVT
Jun 05, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $16.59
Real-time Price: $13.85 info
Change: -$2.74 (-17%) info
Market Cap: $800.711M info